ASCUPRUBART
UNII TS859GZ9C7

Substance Identification & Data

This profile provides standardized clinical and technical data for Ascuprubart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) TS859GZ9C7.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3056020-15-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

TS859GZ9C7

CAS Registry Number

3056020-15-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ASCUPRUBART

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13837

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ascuprubart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ASCUPRUBART

Common Names & Synonyms

ASCUPRUBART [INN]

H-GAMMA2-4 CHIMERISOTYPE HEAVY CHAIN G2(11AAG4) HUMANIZED (1-448) (VH (HOMO SAPIENS IGHV3-23*04 (81.0%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT (9.10.13) (26-34.51-60.99-111)) (1-122) -HOMO SAPIENS IGHG2*01 6-G2V94 CH2 Q30, Y85.2, L92, S115, S116, A124, CH3 Q11, V84, R88, E98, L125 (CH1 (123-220), HINGE 1-15 (221-232), CH2 H30>Q (269), F85.2>Y (301), V92>L (310), A115>S (331), P116>S (332), T124>A (340) (233-341), CH3 R11>Q (356), M84>V (398), K88>R (410), Q98>E (420), P125>L (446) (342-446), CHS (447-448)) (123-448)), (136-217')-DISULFIDE WITH L-KAPPA LIGHT CHAIN HUMANIZED (1'-217') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (90.2%) -IGKJ1*01 (100%), CDR-IMGT (6.3.12) (27'-32'.50'-52'.89'-100')) (1'-110') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (156'), V101 (194')) (111'-217')); DIMER (224-224'': 225-225'':228-228'':231-231'')-TETRAKISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

IMMUNOGLOBULIN G, ANTI-(COMPLEMENT C5 MG4 DOMAIN)(HUMAN CLONE HRA-06-H2-7 .GAMMA.-CHAIN) AND IMMUNOGLOBULIN G, ANTI-(COMPLEMENT C5 MG4 DOMAIN)(HUMAN CLONE HRA-06-H2-1 LIGHT CHAIN) DIMER

IMMUNOGLOBULIN, ANTI-(HUMAN COMPLEMENT 5) (HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL IM-101 HEAVY CHAIN VARIABLE REGION) FUSION PROTEIN WITH IMMUNOGLOBULIN G2 (HUMAN .GAMMA.2-CHAIN CH1-HINGE FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G4 (HUMAN .GAMMA.4-CHAIN CH2-CH3 FRAGMENT), DISULFIDE WITH HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL IM-101 .KAPPA.-CHAIN, DIMER

IMUNOGLOBULIN H-GAMMA2-4 CHIMERISOTYPE G2(11AAG4)-KAPPA, ANTI-(HOMO SAPIENS C5 (COMPLEMENT 5)), HUMANIZED MONOCLONAL ANTIBODY (ASCUPRUBART)

Technical Codes

IM-101

External Clinical & Regulatory Resources

Previous UNIITS8404B04G

Next UNIITS863O3CUZ